<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Shilpa Medicare Limited — News on 6ix</title>
<link>https://6ix.com/company/shilpa-medicare-limited</link>
<description>Latest news and press releases for Shilpa Medicare Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Feb 2026 14:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/shilpa-medicare-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364f6678dffbe2df154e71.webp</url>
<title>Shilpa Medicare Limited</title>
<link>https://6ix.com/company/shilpa-medicare-limited</link>
</image>
<item>
<title>SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/steincares-and-shilpa-biologicals-strike-into-licensing-agreement-to-expand-access-to-biosimilars-across-latin-america</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/steincares-and-shilpa-biologicals-strike-into-licensing-agreement-to-expand-access-to-biosimilars-across-latin-america</guid>
<pubDate>Wed, 25 Feb 2026 14:00:00 GMT</pubDate>
<description>SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), announce a strategic licensing agreement to commercialize a biosimilar across Latin America.</description>
</item>
<item>
<title>Press Release Feb 24 2026</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/press-release-feb-24-2026-15</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/press-release-feb-24-2026-15</guid>
<pubDate>Tue, 24 Feb 2026 15:43:58 GMT</pubDate>
<description>Shilpa Medicare Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Press Release".</description>
</item>
<item>
<title>Press Release Jan 28 2026</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/press-release-jan-28-2026-43</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/press-release-jan-28-2026-43</guid>
<pubDate>Wed, 28 Jan 2026 19:33:30 GMT</pubDate>
<description>Shilpa Medicare Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Shilpa Medicare and mAbTree Biologics receive FDA Orphan Drug Designation, Advancing Treatment for Rare Blood Cancers".</description>
</item>
<item>
<title>Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/shilpa-pharma-lifesciences-awarded-ecovadis-gold-medal-for-outstanding-sustainability-practices</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/shilpa-pharma-lifesciences-awarded-ecovadis-gold-medal-for-outstanding-sustainability-practices</guid>
<pubDate>Tue, 11 Nov 2025 14:15:00 GMT</pubDate>
<description>Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings.</description>
</item>
<item>
<title>Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/shilpa-medicare-announces-positive-phase-3-results-for-oeristm-a-novel-once-weekly-ondansetron-extended-release-injection-for-chemotherapy-induced-nausea-and-vomiting-cinv</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/shilpa-medicare-announces-positive-phase-3-results-for-oeristm-a-novel-once-weekly-ondansetron-extended-release-injection-for-chemotherapy-induced-nausea-and-vomiting-cinv</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successful completion of its fourth complex clinical program SMLINJ011, with positive topline Phase 3 results for Shilpa's OERIS™ (Ondansetron Extended-Release Injection)—an innovative formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV).</description>
</item>
<item>
<title>Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/shilpa-medicares-norudca-makes-history-as-first-approved-nafld-therapy-worldwide</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/shilpa-medicares-norudca-makes-history-as-first-approved-nafld-therapy-worldwide</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD.</description>
</item>
<item>
<title>Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-groundbreaking-pulmonary-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-groundbreaking-pulmonary-therapeutics</guid>
<pubDate>Mon, 04 Aug 2025 12:00:00 GMT</pubDate>
<description>Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.</description>
</item>
<item>
<title>Press Release Feb 11 2022</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/press-release-feb-11-2022-35</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/press-release-feb-11-2022-35</guid>
<pubDate>Fri, 11 Feb 2022 16:24:58 GMT</pubDate>
<description>Shilpa Medicare Limited has informed the Exchange regarding a press release dated February 11, 2022, titled "Shilpa Medicare Limited through its wholly owned subsidiary Shilpa Biologicals Private Limited has entered in to a strategic tie-up for manufacturing arrangement with Mylab Discovery Solutions".</description>
</item>
<item>
<title>Press Release Oct 14 2021</title>
<link>https://6ix.com/company/shilpa-medicare-limited/news/press-release-oct-14-2021-12</link>
<guid isPermaLink="true">https://6ix.com/company/shilpa-medicare-limited/news/press-release-oct-14-2021-12</guid>
<pubDate>Fri, 15 Oct 2021 01:33:02 GMT</pubDate>
<description>Shilpa Medicare Limited has informed the Exchange regarding a press release dated October 14, 2021, titled "In continuation to the outcome of the Board meeting provided today i.e., 14 October 2021 with regard to issue of 52.75 lacs equity shares on preferential basis to various marquee investors aggregating to Rs. 297.51 crores at a price of Rs. 564 per share, please find enclosed copy of Media Release".</description>
</item>
</channel>
</rss>